Schwere Nahrungsmittelallergie: Können Biologika helfen?

ZUSAMMENFASSUNG

Omalizumab ist das bisher am meisten untersuchte Biologikum bei Nahrungsmittelallergie. Bisherige Studien und Fallberichte sprechen für eine protektive Wirkung von Omalizumab bei schwerer Nahrungsmittelallergie mit rezidivierenden Anaphylaxien nach akzidenteller Ingestion der Allergene. Eine Hinzunahme von Omalizumab zur oralen Toleranzinduktion kann die Nebenwirkungen vermindern, die vertragene Allergenmenge erhöhen und die Zeit bis zum Erreichen der Erhaltungsdosis reduzieren. Ob dieser Effekt auch ohne eine kontinuierliche Gabe von langfristiger Dauer ist, müssen weitere Untersuchungen zeigen.

ABSTRACT

Omalizumab is the most studied biologic for food allergies to date. Previous studies and case reports suggest a protective effect of omalizumab in severe food allergy with recurrent anaphylaxis after accidental ingestion of the allergen. The addition of omalizumab for oral tolerance induction may reduce the side effects, increase the amount of allergen tolerated and reduce the time to reach the maintenance dose. Whether this effect is permanent even without continuous administration will need to be investigated in future.

Schlüsselwörter

Nahrungsmittelallergie Therapie - Biologika Anaphylaxie - orale Toleranzinduktion

Keywords

Food allergy - biologics - anaphylaxis - oral food immunotherapy

• Literatur

• 1 Gupta RS, Warren CM, Smith BM. et al The Public Health Impact of Parent-Reported Childhood Food Allergies in the United States. Pediatrics 2018; 142 (06) e20181235 Pediatrics 2019; 143 (3)
• 2 Roehr CC, Edenharter G, Reimann S. et al Food allergy and non-allergic food hypersensitivity in children and adolescents. Clin Exp Allergy 2004; 34 (10) 1534-1541
• 3 Luyt D, Ball H, Kirk K, Stiefel G. Diagnosis and management of food allergy in children. Paediatrics and Child Health 2016; 26 (07) 287-291
• 4 Stone KD, Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 2010; 125 (02) (Suppl. 02) S 73-80
• 5 Yu W, Freeland DMH, Nadeau KC. Food allergy: immune mechanisms, diagnosis and immunotherapy. Nat Rev Immunol 2016; 16 (12) 751-765
• 6 Holgate S, Casale T, Wenzel S. et al The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005; 115 (03) 459-465
• 7 Vakharia PP, Silverberg JI. New and emerging therapies for paediatric atopic dermatitis. Lancet Child Adolesc Health 2019; 3 (05) 343-353
• 8 Kouro T, Takatsu K. IL-5- and eosinophil-mediated inflammation: from discovery to therapy. Int Immunol 2009; 21 (12) 1303-1309
• 9 Vickery BP. Can Omalizumab Monotherapy Benefit Real-World Food Allergy Patients? Lessons from an Observational Study. J Allergy Clin Immunol Pract 2019; 7 (06) 1910-1911
• 10 ClinicalTrials.gov. Available from: URL: https://www.clinicaltrials.gov/ct2/results?cond=food+allergy&term=Omalizumab&cntry=&state=&city=&dist=&Search=Search&flds=aby&age=0
• 11 Fiocchi A, Riccardi Artesani MC. et al Impact of Omalizumab on Food Allergy in Patients Treated for Asthma: A Real-Life Study. J Allergy Clin Immunol Pract 2019; 7 (06) 1901-1909.e5
• 12 Sampson HA, Leung DYM, Burks AW. et al A phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol 2011; 127 (05) 1309-1310.e1
• 13 Wood RA, Kim JS, Lindblad R. et al A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow’s milk allergy. J Allergy Clin Immunol 2016; 137 (04) 1103-1110.e11
• 14 Takahashi M, Soejima K, Taniuchi S. et al Oral immunotherapy combined with omalizumab for high-risk cow’s milk allergy: a randomized controlled trial. Sci Rep 2017; 7 (01) 17453
• 15 MacGinnitie AJ, Rachid R, Gragg H. et al Omalizumab facilitates rapid oral desensitization for peanut allergy. J Allergy Clin Immunol 2017; 139 (03) 873-881.e8
• 16 Andorf S, Purington N, Block WM. et al Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial. The Lancet Gastroenterology & Hepatology 2018; 3 (02) 85-94
• 17 Yee CSK, Albuhairi S, Noh E. et al Long-Term Outcome of Peanut Oral Immunotherapy Facilitated Initially by Omalizumab. J Allergy Clin Immunol Pract 2019; 7 (02) 451-461.e7
• 18 Rial MJ, Barroso B, Sastre J. Dupilumab for treatment of food allergy. J Allergy Clin Immunol Pract 2019; 7 (02) 673-674
• 19 ClinicalTrials.gov. Available from: URL https://www.clinicaltrials.gov/ct2/results?cond=+food+allergy&term=Dupilumab&cntry=&state=&city=&dist=&Search=Search&flds=aby&age=0
• 20 Just J, Deschildre A, Lejeune S, Amat F. New perspectives of childhood asthma treatment with biologics. Pediatr Allergy Immunol 2019; 30 (02) 159-171